Cancer care cost-effectiveness in low-income and middle-income countries: time to shift the burden of proof

Lancet Glob Health. 2022 Aug;10(8):e1084-e1085. doi: 10.1016/S2214-109X(22)00289-3.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Developing Countries*
  • Humans
  • Income
  • Neoplasms* / therapy
  • Poverty